Cytosorbents Balance Sheet Health
Financial Health criteria checks 2/6
Cytosorbents has a total shareholder equity of $13.0M and total debt of $13.8M, which brings its debt-to-equity ratio to 106.2%. Its total assets and total liabilities are $47.8M and $34.8M respectively.
Key information
106.2%
Debt to equity ratio
US$13.81m
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.69m |
| Equity | US$13.00m |
| Total liabilities | US$34.80m |
| Total assets | US$47.80m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HQE1's short term assets ($16.6M) exceed its short term liabilities ($8.4M).
Long Term Liabilities: HQE1's short term assets ($16.6M) do not cover its long term liabilities ($26.4M).
Debt to Equity History and Analysis
Debt Level: HQE1's net debt to equity ratio (62.5%) is considered high.
Reducing Debt: HQE1's debt to equity ratio has reduced from 223% to 106.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HQE1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HQE1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.1% each year